S M Sirrs1, H Faghfoury, E M Yoshida, T Geberhiwot. 1. Division of Endocrinology, Adult Metabolic Diseases Clinic, Level 4 - 2775 Laurel Street, V5Z 1 M9, Vancouver, BC, Canada, Sandra.Sirrs@vch.ca.
Abstract
BACKGROUND: Transplantation in patients with inborn errors of metabolism (IEM) may be used as rescue therapy for acute decompensation, organ replacement, or disease-modifying therapy. We sought to quantify the use of transplantation in adults with IEM. METHODS: A 10-question online survey was sent through the email list of adult IEM physicians maintained by the Society for the Study of Inborn Errors of Metabolism and posted on the website of the Society of Inherited Metabolic Diseases. RESULTS: Thirteen centers from five continents responded. These centers, ranging in size from <50 adult patients (three centers) to >500 (two centers), reported 57 adult patients who had undergone transplantation. 29/57 (51 %) came from the two largest centers and 27/57(47 %) were renal transplants for Fabry disease (FD). Only seven transplants were identified as being done for acute decompensation. Eight of thirteen centers had not had patients with IEM passed over on the transplant list but four of these eight had not referred a patient for transplantation. 4/13 centers had patients passed over on the transplant list and reasons cited included: (a) transplant team not comfortable with underlying disease, (b) cognitive impairment in patient raised concerns about compliance, (c) multisystem disease makes single organ transplantation inappropriate, and (d) not at enough risk of life-threatening decompensation. CONCLUSIONS: Excluding renal transplantation for FD, there is low use of transplantation in adults with IEM. Some barriers to transplantation reported by adult centers could be improved with development of educational and management modules for both transplant and metabolic programs.
BACKGROUND: Transplantation in patients with inborn errors of metabolism (IEM) may be used as rescue therapy for acute decompensation, organ replacement, or disease-modifying therapy. We sought to quantify the use of transplantation in adults with IEM. METHODS: A 10-question online survey was sent through the email list of adult IEM physicians maintained by the Society for the Study of Inborn Errors of Metabolism and posted on the website of the Society of Inherited Metabolic Diseases. RESULTS: Thirteen centers from five continents responded. These centers, ranging in size from <50 adult patients (three centers) to >500 (two centers), reported 57 adult patients who had undergone transplantation. 29/57 (51 %) came from the two largest centers and 27/57(47 %) were renal transplants for Fabry disease (FD). Only seven transplants were identified as being done for acute decompensation. Eight of thirteen centers had not had patients with IEM passed over on the transplant list but four of these eight had not referred a patient for transplantation. 4/13 centers had patients passed over on the transplant list and reasons cited included: (a) transplant team not comfortable with underlying disease, (b) cognitive impairment in patient raised concerns about compliance, (c) multisystem disease makes single organ transplantation inappropriate, and (d) not at enough risk of life-threatening decompensation. CONCLUSIONS: Excluding renal transplantation for FD, there is low use of transplantation in adults with IEM. Some barriers to transplantation reported by adult centers could be improved with development of educational and management modules for both transplant and metabolic programs.
Authors: Frank Weidemann; Claudia Sommer; Thomas Duning; Ines Lanzl; Matthias Möhrenschlager; Dennis Naleschinski; Kathrin Arning; Ralf Baron; Markus Niemann; Frank Breunig; Roland Schaefer; Jörg Strotmann; Christoph Wanner Journal: Am J Med Date: 2010-07 Impact factor: 4.965
Authors: George V Mazariegos; D Holmes Morton; Rakesh Sindhi; Kyle Soltys; Navdeep Nayyar; Geoffrey Bond; Diana Shellmer; Benjamin Shneider; Jerry Vockley; Kevin A Strauss Journal: J Pediatr Date: 2011-08-11 Impact factor: 4.406
Authors: Richard B Freeman; Robert G Gish; Ann Harper; Gary L Davis; John Vierling; Leslie Lieblein; Goran Klintmalm; Jamie Blazek; Robert Hunter; Jeffrey Punch Journal: Liver Transpl Date: 2006-12 Impact factor: 5.799
Authors: Peter J Mc Guire; Elizabeth Lim-Melia; George A Diaz; Kimiyo Raymond; Alexandra Larkin; Melissa P Wasserstein; Claude Sansaricq Journal: Mol Genet Metab Date: 2007-10-26 Impact factor: 4.797
Authors: Robert F Wynn; J Ed Wraith; Jean Mercer; Anne O'Meara; Karen Tylee; Margaret Thornley; Heather J Church; Brian W Bigger Journal: J Pediatr Date: 2009-04 Impact factor: 4.406
Authors: Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh Journal: N Engl J Med Date: 2007-05-31 Impact factor: 91.245
Authors: Sandra Sirrs; Fady Hannah-Shmouni; Stephen Nantel; James Neuberger; Eric M Yoshida Journal: J Inherit Metab Dis Date: 2018-02-01 Impact factor: 4.982